Cell Cycle Control by Oncogenes and Tumor Suppressors: Driving the Transformation of Normal Cells into Cancerous Cells. By: Amy Y. Chow, Ph.D. (Division of Tumor Cell Biology, Beckman Research ...

This review of oncogene-induced cell senescence describes a physiological mechanism that provides protection against cancer. The mechanisms underlying the arrest of growth in benign or premalignant ...

Oncogenes that promote cell-cycle progression also sensitize cells to agents that induce apoptosis. Sensitization is thought to be caused by the induction of proapoptotic factors. Alternatively ...

Proto-oncogenes are a group of genes that normally regulate cell division and growth by encoding regulator proteins for cell cycle, growth factors, transcription factors, DNA-binding proteins, and ...

Oncogenes in AML. The number of chromosomal alterations observed in AML [2,3] (more than 200 translocations, in addition to several point mutations) is enormous and makes it impossible to screen ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may play an important role in colon cancer. Researchers also showed how this ...

Proto-oncogenes have many functions in a cell but they often code for proteins that stimulate cell division, prevent cell differentiation or regulate programmed cell death (apoptosis).

Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic setting but also ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a white blood cell that makes antibodies and helps you fight infection. The cancer ...

Investigating how mutations in tumors alter DNA’s 3D structure—and subsequently, regulatory sequences called enhancers—can ...

2 Chowdhry et al. Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition [abstract]. Cancer Res 2023 ...

Druggable oncogene-driven non–small cell lung cancer (NSCLC) has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic ...